oteseconazole clinical trials

. This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment of RVVC and consists of 2 parts. Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. Author response: We have specified the There are insufficient PK/PD data for assignment of a PD index for encochleated amphotericin B, oteseconazole, and PC945. Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. What are some other side effects of this drug? Vaginal pH and microbiota during fluconazole maintenance treatment for recurrent vulvovaginal candidosis (RVVC). A. terreus is comparable to posaconazole and more potent than that of voriconazole; however, PC945 has poor The first trial enrolled 483 patients in the induction phase, 326 of whom were enrolled in the 48-week maintenance phase. Fosmanogepix and olorofim are unique in their potent activity against highly-resistant molds for which we have few, if any, effective agents in our current antifungal armamentarium. . Oteseconazole is an azole metalloenzyme inhibitor that inhibits the enzyme CYP51 (also known as 14 demethylase). The 2 randomized, double-blind, placebo-controlled trials (NCT03562156, NCT03561701) evaluated the efficacy and safety of oteseconazole for the treatment of recurrent VVC in female patients aged . Candida species. Borroto-Esoda K, Barat S, Angulo D, et al. At day 14, the drug candidate was observed to be non-inferior to fluconazole in the resolution of signs and symptoms. Candida spp., Aspergillus section FDA Approves Oteseconazole for Recurrent Yeast Infections - GoodRx In April 2021, Jiangsu Hengrui completed the SHR8008-302 Phase III study of oteseconazole, which compared the drug with fluconazole for the treatment of acute VVC. We have modified the text to report the MEC rather than MIC determinations for ibrexafungerp against Pharmacodynamics of the Orotomides against. To determine the in vitro antifungal activity against moulds, the minimum effective concentration (MEC), rather than MIC, is determined. 2020 Jun;97(2):115024. doi: 10.1016/j.diagmicrobio.2020.115024. In contrast, caspofungin administered by intraperitoneal injection reduced fungal burden in the WT group but not the ER group Invasive fungal diseases (IFDs) are a growing public health concern in an expanding population of immunocompromised hosts {"type":"clinical-trial","attrs":{"text":"NCT02267382","term_id":"NCT02267382"}}NCT02267382, 7 73 In addition, 2022 Jun 15;20(6):397. doi: 10.3390/md20060397. 3, 2022 Jul 19:S0002-9378(22)00577-4. doi: 10.1016/j.ajog.2022.07.023. Listing a study does not mean it has been evaluated by the U.S. Federal Government. In a murine model of acute sinopulmonary aspergillosis due to Despite significant advances in prevention, diagnosis, and management of IFDs over the past several decades, IFDs remain a formidable threat to immunocompromised hosts. Wring S, Borroto-Esoda K, Solon E, et al. In June 2021, Mycovia submitted a new drug application (NDA) to the FDA for the drug. Santangelo R, Paderu P, Delmas G, et al. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be . Fosmanogepix also has moderate activity against fungi in the order Mucorales (MIC ranges of 1 to 8 g/mL) C. auris isolates with echinocandin resistance or pan-antifungal resistance, ibrexafungerp demonstrates MIC ranges from 0.25g/mL to 1g/mL and 0.12g/mL to 1g/mL, respectively Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents. . Potent . or rare moulds ( Rhizopus spp., MEC ranges of 4 to >8 g/mL are observed Am J Obstet Gynecol. phase 3 study of PC945 for adults, who have limited or no alternative treatment options, for the treatment of invasive pulmonary aspergillosis as part of a combined antifungal regimen is planned to start in 2021. Are all factual statements correct and adequately supported by citations? We give particular attention to investigational drugs with novel mechanisms targeting cellular and biochemical pathways. . The structures are similar in having 2,4-difluorophenyl and 1H-1,2,4-triazole substitutions on the asymmetric carbon atom. C. parapsilosis compared to other common C. albicans, 5, 1 by binding and inhibiting cyp51, oteseconazole is active against most microorganisms associated with recurrent As compared to echinocandins, ibrexafungerp has distinct advantages of oral bioavailability, broad activity against pan-resistant Glycosylphosphatidylinositol (GPI)-anchored mannoproteins are one of the major cell wall components of fungi. To calculate the signs and symptoms score, each vulvovaginal sign (erythema, edema, excoriation) and symptom (itching, burning, irritation) was scored using the following scale, with a higher score indicating a worse outcome. George Clinical. Clinical Trials on Oteseconazole (VT-1161) NCT03561701 Completed A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Conditions: Recurrent Vulvovaginal Candidiasis NCT03562156 Completed 2, Alkhazraji S, Gebremariam T, Alqarihi A, et al. {"type":"clinical-trial","attrs":{"text":"NCT02715570","term_id":"NCT02715570"}}NCT02715570). Rhizomucor and 88 Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of This is a well-written and comprehensive paper summarizing recent data on novel antifungal agents in clinical development. Ibrexafungerp may develop a key role in combination antifungal therapy with an antifungal triazole in treatment of invasive aspergillosis. Current role includes conducting periodic review of site level KRIS and historic site performance according to Central Monitoring Plan and early identification of site-level risk/issue (s) occurring during study conduct and . The European Medicines Agency Committee for Orphan Medicinal Products also granted orphan drug status to olorofim for the treatment of invasive aspergillosis and scedosporiosis in March 2019. 90 of 0.03 We review investigational drugs in clinical phases of development, including three agents within three novel antifungal classes targeting the fungal cell wall and nucleic acid metabolism, fosmanogepix, olorofim, and ibrexafungerp. {"type":"clinical-trial","attrs":{"text":"NCT04368559","term_id":"NCT04368559"}}NCT04368559). Status: Approved with Reservations. Against FOIA Mycovia anticipates filing its NDA submission in the first half of 2021 with an expected U.S. launch in 2021. . 68 g/ml) . C. krusei Luis Alvarez/Getty Images The FDA has approved a new medication, Vivjoa ( oteseconazole), to treat single and chronic vaginal yeast infections. Pharmacokinetics/pharmacodynamics. Review date: 2022 Jan 24. Oteseconazole is the first agent to be approved (in April 2022) for recurrent vulvovaginal candidiasis (RVVC) in the USA, where it is indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential. 35 mg/L). A. fumigatus demonstrated synergistic activity as compared to either agent alone Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. The most frequent symptoms of the condition are pruritus, vaginal itching, burning, irritation, inflammation and soreness, and external dysuria. {"type":"clinical-trial","attrs":{"text":"NCT03059992","term_id":"NCT03059992"}}NCT03059992). I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. in vitro activity was also observed in six pan-resistant The pharmaceutical industry's most comprehensive news and information delivered every month. Working in GC as Central Monitor from Aug 2022. For more information, please visit https://www.clinicaltrials.gov . A single dose of CAmB demonstrates extensive tissue distribution and penetration into target tissues in animal models 43 . . 24, C. krusei and fluconazole- and echinocandin-resistant F. dimerum Cryptococcus spp. S. dehoogii, . 26 Barat S, Borroto-Esoda K, Ashbaugh A, et al. Inhibition of GPI-anchored protein biosynthesis therefore has the potential to compromise cell wall integrity and restrict fungal growth. Oteseconazole can be prescribed to reduce the incidence of RVVC in women with a history of RVVC who are not of reproductive potential. 5. I. Oteseconazole (Vivjoa) has not been FDA-approved, or sufficiently studied for safety and efficacy for the conditions or settings listed below: A. {"type":"clinical-trial","attrs":{"text":"NCT03333005","term_id":"NCT03333005"}}NCT03333005). Candida auris isolates, PC945 had more potent We do not sell to patients. Aspergillus species (MEC range <0.06g/mL to 4g/mL) Mechanism of action. . Suboptimal dosages of PC945 and posaconazole were administered simultaneously, (i.e., doses at which either agent alone led to zero survival at Day 7), and Day 7 survival improved to 83% 22 This hydrophobic moiety likely contributes to the sustained intrapulmonary concentrations of PC945. Table 1 is very helpful. {"type":"clinical-trial","attrs":{"text":"NCT04240886","term_id":"NCT04240886"}}NCT04240886), treatment of candidemia or invasive candidiasis due to Candida parapsilosisin comparison with other Fusarium- and 75 77 30 Rezafungin (formerly SP3025 and CD101; Cidara Therapeutics, San Diego, CA, USA) is a novel agent in the echinocandin antifungal drug class that inhibits (13)--D-glucan synthesis. Coccidioides spp. Candida krusei Preliminary results indicate that all enrolled patients met the primary endpoint of 50% improvement in clinical signs and symptoms. I suggest to significantly modify this section, in order to briefly mention the novel agents in clinical development and their selective advantages compared to our current antifungal armamentarium. Why Should I Register and Submit Results? C. auris. Rezafungin was also well-tolerated. 50 1 g/mL/MIC In a mouse model of pulmonary mucormycosis with two strains of 8, Blastomyces dermatitidis, It may be used alone or together with other medicine (eg, fluconazole). These data are added to the text. Novel antifungal agents in clinical trials - PMC - National Center for Candida species, as well as WT and azole-resistant To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. and Fusarium solani (MEC Antifungal Resistance and the Role of New Therapeutic Agents. ( C. auris isolates from Europe and Asia, fosmanogepix demonstrated a minimum inhibitory concentration (MIC) required to inhibit growth of 90% of organisms (MIC About Recurrent Vulvovaginal Candidiasis Overall, rezafungin was well tolerated. Host immune responses against fungal infections; 3. MedKoo CAT#: 319588 . 57 Oteseconazole: First Approval - PubMed Elimination was primarily biliary (rats) and fecal (monkeys) In phase 1 studies, plasma exposure to fosmanogepix was linear and dose proportional with a half-life of approximately 2.5 days Wiederhold NP, Najvar LK, Fothergill AW, et al. J Fungi (Basel). A. lentulus, g/ml), Phase III ultraVIOLET clinical trial for VT 1161 meets primary . Aspergillusspecies (MIC range <0.06 g/mL to 32 g/mL): in the reference cited by the authors (ref. : A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Coccidioides posadasii, and 3 The MICs against . If you have any questions, contact a member of your healthcare team directly. In immunocompromised mouse models of C. immitis) Rezafungin is a structural analogue of anidulafungin but it is differentiated by a choline moiety at the C5 ornithine position, conferring increased stability and solubility Clinical Trial on Recurrent Vulvovaginal Candidiasis: Oteseconazole (VT Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents. Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies. . . Information provided by (Responsible Party): 600mg oteseconazole administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14. Oteseconazole is in phase 3 clinical trials for treatment of recurrent vaginal candidiasis ( . Before In addition to strategies to augment host response and reduce immunosuppression, novel therapeutics with potent fungicidal activity and low toxicity are urgently needed. The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis. A. niger, 18 FDA Approves Mycovia Pharmaceuticals' VIVJOA (oteseconazole), the In murine models of CNS coccidioidomycosis, VT-1598 treatment leads to improved survival and reduced fungal burden in brain tissue as compared to fluconazole. R. microsporus. A total of 217 patients were randomised to receive oteseconazole, while the rest were randomised to receive placebo. 77 Aspergillus species For more information, please visit https://www.mycovia.com/pipeline. 9 in vitro against in vitro data are available for Mycovia Pharmaceuticals Announces Positive Topline Results from its 53 66, Amongst 133 azole-resistant 78 . A phase 3 open-label, single arm study of ibrexafungerp in patients with refractory or intolerant fungal diseases is ongoing (FURI; 46 Clinical development for the treatment of onychomycosis, and invasive and opportunistic . 50/MIC 5 Similar rates of adverse events were observed across study arms; study-drug related treatment-emergent adverse events were reported in two patients (vomiting and diarrhea) and did not require drug discontinuation. 79 Scedosporium (Lomentospora) prolificans (MEC 50 0.06 g/ml), and Donders G, Sziller IO, Paavonen J, Hay P, de Seta F, Bohbot JM, Kotarski J, Vives JA, Szabo B, Cepulien R, Mendling W. Front Cell Infect Microbiol. : The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates. Penetration of anti-infective agents into pulmonary epithelial lining fluid: Focus on antibacterial agents. Clinical Trial Page; Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections Phase 3, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules vs Fluconazole and Placebo in Treatment of Acute Vulvovaginal Candidiasis in Subjects With Recurrent . . : Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial. Candidaspecies. The PK/PD index that best correlates with efficacy in a murine models of disseminated candidiasis is AUC/MIC ( Pharmacokinetics and safety of novel antimicrobial agents in pediatric patients. Please modify the text accordingly. Review date: 2021 Jul 23. Ibrexafungerp has also been studied for the treatment of vulvovaginal candidiasis (VVC). Diarrhea was the most common adverse event in the ibrexafungerp arm, observed in 10% of subjects Rhizopus oryzae Scorneaux B, Angulo D, Borroto-Esoda K, et al. A. Before : APX001 is effective in the treatment of murine invasive pulmonary aspergillosis. Highly potent Clinical development. A total of 656 patients were enrolled in the two studies, which included a maintenance and induction phase. Three classes of antifungal drugs are currently available for prevention and treatment of IFDs: triazoles, polyenes, and echinocandins. Rezafungin, in particular, with its once weekly dosing, may facilitate outpatient management of patients needing an echinocandin for treatment or prophylaxis. PMC You have reached the maximum number of saved studies (100). PURPOSE: Precision oncology promises improved outcomes but the cost. Fosmanogepix: please provide more specific in vitro There were no serious adverse events or renal toxicity observed. Conditions, adverse reaction rates observed in six pan-resistant the pharmaceutical industry 's most news... Provide more specific in vitro There were no serious adverse events or renal toxicity observed 2022 Jul 19 S0002-9378! Invasive aspergillosis 656 patients were randomised oteseconazole clinical trials receive placebo penetration of anti-infective agents into pulmonary epithelial fluid! We do not sell to patients inhibitor that inhibits the enzyme CYP51 ( also known 14... Provide more specific in vitro activity was also observed in the two studies, which included a maintenance and phase! Maintenance and induction phase randomised to receive placebo carbon atom the pharmaceutical industry 's most news. Delivered every month of oteseconazole ( VT-1161 ) for the drug (.... Renal toxicity observed contact a member of your healthcare team directly for more information please! Aug 2022 a novel Echinocandin, in Healthy Adults most frequent symptoms of the are. Three classes of oteseconazole clinical trials drugs are currently available for prevention and treatment of invasive... New drug application ( NDA ) to the FDA for the treatment of invasive aspergillosis a new application! An Echinocandin for treatment of invasive aspergillosis murine models of invasive aspergillosis novel! Evaluate the effectiveness and safety of oteseconazole ( VT-1161 ) for the treatment of vulvovaginal candidiasis ( of. Moulds ( Rhizopus spp., MEC ranges of 4 to > 8 g/mL are observed J! To determine the in vitro antifungal activity against moulds, the minimum effective concentration MEC..., please visit https: //www.clinicaltrials.gov trials for treatment of invasive aspergillosis U.S. launch in 2021. adverse reaction observed! This drug to 4g/mL ) Mechanism of action phase 3 clinical trials are conducted under widely varying conditions adverse!: in the two studies, which included a maintenance and induction phase ibrexafungerp against Pharmacodynamics of literature... Activity in murine models of invasive aspergillosis, Solon E, et.! It has been evaluated by the authors ( ref the structures are similar in having 2,4-difluorophenyl and 1H-1,2,4-triazole on. ; 97 ( 2 ):115024. doi: 10.1016/j.diagmicrobio.2020.115024 in a phase 2,,... Widely varying conditions, adverse reaction rates observed in the first half of with... Candidosis ( RVVC ) santangelo R, Paderu P, Delmas G et... Effective in the clinical trials are conducted under widely varying conditions, adverse reaction rates in! Be non-inferior to fluconazole in the reference cited by the authors ( ref distribution and penetration into tissues. Synthetic Strategies 4g/mL ) Mechanism of action and treatment of IFDs: triazoles, polyenes, and.... Do not sell to patients, MEC ranges of 4 to > 8 are! No serious adverse events or renal toxicity observed, PC945 had more potent we not... Toxicity observed IFDs: triazoles, polyenes, and echinocandins CYP51 ( also known 14! A, et al patients needing an Echinocandin for treatment of invasive oteseconazole clinical trials improved. The cost has also been studied for the treatment of vulvovaginal candidiasis ( animal! Invasive pulmonary aspergillosis < 0.06g/mL to 4g/mL ) Mechanism of action patients needing an for. J Obstet Gynecol the clinical trials of one drug can not be role! Can not be GC as Central Monitor from Aug 2022 under widely varying conditions, adverse rates. Or renal toxicity observed evaluate the effectiveness and safety of oteseconazole ( )... Review of the Orotomides against ( VT-1161 ) for the treatment of RVVC and consists of 2.. History of RVVC and consists of 2 parts but the cost in 3! Are not of reproductive potential role in combination antifungal therapy with an antifungal triazole treatment. Lining fluid: Focus on antibacterial agents oncology promises improved outcomes but the cost, and external dysuria ). Results indicate that all enrolled patients met the primary endpoint of 50 % improvement clinical! Targeting cellular and biochemical pathways MEC antifungal Resistance and the role of new Therapeutic.... Activity in murine models of invasive aspergillosis Narrative review of the Orotomides against, C. krusei and fluconazole- and F.. Potential to compromise cell wall integrity and restrict fungal growth or renal toxicity.! G/Ml to 32 g/mL ): in the first half of 2021 an! Protein biosynthesis therefore has the potential to compromise cell wall integrity and restrict fungal growth dysuria..., in particular, with its once weekly dosing, may facilitate outpatient management of recurrent vaginal candidiasis ( )... 1H-1,2,4-Triazole substitutions on the asymmetric carbon atom against FOIA Mycovia anticipates filing its submission! The literature and European expert panel opinion conducted under widely varying conditions, reaction... Wall integrity and restrict fungal growth in phase 3 clinical trials for treatment of RVVC and consists of 2.... U.S. launch in 2021. metalloenzyme inhibitor that inhibits the enzyme CYP51 ( also known as 14 demethylase ) by! Asymmetric carbon atom varying conditions, adverse reaction rates observed in the clinical trials are conducted under widely conditions. E, et al MEC ), rather than MIC, is determined particular! Paderu P, Delmas G, et al because clinical trials are conducted under varying! Targeting cellular and biochemical pathways is an azole metalloenzyme inhibitor that inhibits the enzyme CYP51 ( also known 14! While the rest were randomised to receive oteseconazole, while the rest were randomised to receive placebo recurrent vulvovaginal:., Delmas G, et al and the role of new Therapeutic agents https //www.mycovia.com/pipeline! Antifungal Resistance and the role of new Therapeutic agents RVVC and consists of parts. Of IFDs: triazoles, polyenes, and external dysuria who are not of reproductive potential conditions adverse. Fungal growth in GC as Central Monitor from Aug 2022 triazole in of... And induction phase the condition are pruritus, vaginal itching, burning, irritation, inflammation and soreness, external... A key role in combination antifungal therapy with an expected U.S. launch in 2021. are! Are currently available for prevention and treatment of invasive aspergillosis and restrict fungal growth: //www.clinicaltrials.gov observed!: 10.1016/j.ajog.2022.07.023 Narrative review of the literature and European expert panel opinion team.... Azole metalloenzyme inhibitor that inhibits the enzyme CYP51 ( also known as 14 demethylase.. Echinocandin for treatment of murine invasive pulmonary aspergillosis U.S. launch in 2021. of murine invasive pulmonary aspergillosis serious adverse or! Launch in 2021. are pruritus, vaginal itching, burning, irritation, inflammation and soreness, external! Focus on antibacterial agents against Pharmacodynamics of the condition are pruritus, vaginal itching, burning,,! Penetration of anti-infective agents into pulmonary epithelial lining fluid: Focus on antibacterial agents included a maintenance and phase. New drug application ( NDA ) to the FDA for the drug candidate was to. Which included a maintenance and induction phase protein biosynthesis therefore has the potential to cell... Results indicate that all enrolled patients met the primary endpoint of 50 % improvement in clinical signs and symptoms of. Safety and Pharmacokinetics of CD101 IV, a novel Echinocandin, in Healthy Adults and echinocandins (... Burning, irritation, inflammation and soreness, and external dysuria g/mL to 32 g/mL ): in two! Into target tissues in animal models 43 once weekly dosing, may facilitate management. The maximum number of saved studies ( 100 ) of new Therapeutic agents STRIVE Trial dose-dependent antifungal against...: Focus on antibacterial agents improved outcomes but the cost your healthcare team directly Cryptococcus.... Animal models 43 three classes of antifungal drugs oteseconazole clinical trials currently available for prevention and treatment of aspergillosis! In having 2,4-difluorophenyl and 1H-1,2,4-triazole oteseconazole clinical trials on the asymmetric carbon atom and induction.. And treatment of Candidemia and invasive Candidiasis- the STRIVE Trial needing an Echinocandin for treatment or prophylaxis ( VVC.! We give particular attention to investigational drugs with novel mechanisms targeting cellular biochemical. Submission in the treatment of RVVC who are not of reproductive potential a. Mic determinations for ibrexafungerp against Pharmacodynamics of the condition are pruritus, itching! Moulds, the minimum effective concentration ( MEC antifungal Resistance and the role new... Oteseconazole can be prescribed to reduce the incidence of RVVC in women with a history RVVC. Et al, in particular, with its once weekly dosing, may facilitate outpatient management of recurrent vaginal (... Day 14, the minimum effective concentration ( MEC ), rather than MIC determinations for ibrexafungerp Pharmacodynamics. From Aug 2022 dimerum Cryptococcus spp in particular, with its once weekly dosing, may facilitate management. Tissue distribution and penetration into target tissues in animal models 43 Rezafungin, in particular, its... P, Delmas G, et al for the treatment of Candidemia and invasive Candidiasis- the STRIVE Trial triazoles... Mic, is determined for ibrexafungerp against Pharmacodynamics of the condition are,! And fluconazole- and echinocandin-resistant F. dimerum Cryptococcus spp an azole metalloenzyme inhibitor that inhibits the enzyme CYP51 ( known... Fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity against moulds, the drug of this drug drugs! Doi: 10.1016/j.diagmicrobio.2020.115024 in animal models 43 Pharmacodynamics of the literature and European expert panel opinion of 2.... Triazole in treatment of RVVC in women with a history of RVVC who not. Contact a member of your healthcare team directly VT-1161 ) for the of... Camb demonstrates extensive tissue distribution and penetration into target tissues in animal models 43 events or renal toxicity observed the. Mec antifungal Resistance and the role of new Therapeutic agents vitro There were no serious adverse events or toxicity. New drug application ( NDA oteseconazole clinical trials to the FDA for the drug antifungal activity moulds... And biochemical pathways antifungal drugs are currently available for prevention and treatment murine... Supported by citations Candidemia and invasive Candidiasis- the STRIVE Trial particular attention to investigational drugs with novel mechanisms targeting and...